search icon
neup-img

Neuphoria Therapeutics Inc, Common Stock

NEUP

NMQ

$6.48

-$0.04

(-0.61%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$11.71M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0.452
Volume info-icon
This is the total number of shares traded during the most recent trading day.
5.73K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.12 L
$12.72 H
$6.48

About Neuphoria Therapeutics Inc, Common Stock

Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7, which is in phase 3 clinical trial for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. In addition, it develops NextGen, which is in preclinical trial for the treatment of multiple central nervous system indications; Kv3.1/3.2 agonist, which is in preclinical trial to treat potential cognitive deficits and negative symptoms/social withdrawal in schizophrenia and autism spectrum disorders; and Nav1.7/1.8 inhibitors which is in preclinical trial for the potential treatment of chronic pain without the liability of addiction associated with opioid treatment. The company has a collaboration with Merck & Co., Inc. to develop a7 receptor positive allosteric modulators targeting cognitive dysfunction associated with alzheimer's disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Burlington, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameNEUPSectorS&P500
1-Week Return4.01%0.71%0.79%
1-Month Return25.22%-5.6%6.04%
3-Month Return24.62%-11.72%-1.11%
6-Month Return80%-10.81%-2.39%
1-Year Return-43.93%-7.12%11.69%
3-Year Return-92.86%-0.57%42.29%
5-Year Return-96.33%27.64%93.12%

Financials

Jun '20Jun '21Jun '22Jun '23Jun '245YR TREND
Total Revenue32.06K-181.36K--[{"date":"2020-06-30","value":17.68,"profit":true},{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":100,"profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true}]
Cost of Revenue-----[{"date":"2020-06-30","value":"-","profit":true},{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true}]
Gross Profit32.06K-181.36K--[{"date":"2020-06-30","value":17.68,"profit":true},{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":100,"profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true}]
Gross Margin100.00%-100.00%--[{"date":"2020-06-30","value":100,"profit":true},{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":100,"profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true}]
Operating Expenses6.23M8.96M14.86M21.56M17.89M[{"date":"2020-06-30","value":28.88,"profit":true},{"date":"2021-06-30","value":41.55,"profit":true},{"date":"2022-06-30","value":68.93,"profit":true},{"date":"2023-06-30","value":100,"profit":true},{"date":"2024-06-30","value":82.99,"profit":true}]
Operating Income(6.19M)(8.96M)(14.68M)(21.56M)(17.89M)[{"date":"2020-06-30","value":-619414849,"profit":false},{"date":"2021-06-30","value":-895765463,"profit":false},{"date":"2022-06-30","value":-1468103640,"profit":false},{"date":"2023-06-30","value":-2156023400,"profit":false},{"date":"2024-06-30","value":-1789237600,"profit":false}]
Total Non-Operating Income/Expense-1.20M(442.97K)362.54K2.53M[{"date":"2020-06-30","value":"-","profit":true},{"date":"2021-06-30","value":47.45,"profit":true},{"date":"2022-06-30","value":-17.49,"profit":false},{"date":"2023-06-30","value":14.31,"profit":true},{"date":"2024-06-30","value":100,"profit":true}]
Pre-Tax Income(4.14M)(6.68M)(15.10M)(21.52M)(15.58M)[{"date":"2020-06-30","value":-414098808,"profit":false},{"date":"2021-06-30","value":-667522991,"profit":false},{"date":"2022-06-30","value":-1510041137,"profit":false},{"date":"2023-06-30","value":-2152085100,"profit":false},{"date":"2024-06-30","value":-1557948600,"profit":false}]
Income Taxes(142.65K)(140.82K)(131.95K)(139.17K)(87.32K)[{"date":"2020-06-30","value":-14265434,"profit":false},{"date":"2021-06-30","value":-14082091,"profit":false},{"date":"2022-06-30","value":-13194651,"profit":false},{"date":"2023-06-30","value":-13917400,"profit":false},{"date":"2024-06-30","value":-8732000,"profit":false}]
Income After Taxes-(6.53M)(14.97M)(21.38M)(15.49M)[{"date":"2020-06-30","value":"-","profit":true},{"date":"2021-06-30","value":-653440900,"profit":false},{"date":"2022-06-30","value":-1496846486,"profit":false},{"date":"2023-06-30","value":-2138167700,"profit":false},{"date":"2024-06-30","value":-1549216600,"profit":false}]
Income From Continuous Operations-(6.53M)(14.97M)(21.38M)(15.49M)[{"date":"2020-06-30","value":"-","profit":true},{"date":"2021-06-30","value":-653440900,"profit":false},{"date":"2022-06-30","value":-1496846486,"profit":false},{"date":"2023-06-30","value":-2138167700,"profit":false},{"date":"2024-06-30","value":-1549216600,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-06-30","value":"-","profit":true},{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true}]
Net Income(4.89M)(6.53M)(14.97M)(21.38M)(15.49M)[{"date":"2020-06-30","value":-489111760,"profit":false},{"date":"2021-06-30","value":-653440900,"profit":false},{"date":"2022-06-30","value":-1496846486,"profit":false},{"date":"2023-06-30","value":-2138167700,"profit":false},{"date":"2024-06-30","value":-1549216600,"profit":false}]
EPS (Diluted)-----[{"date":"2020-06-30","value":"-","profit":true},{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

NEUP
Cash Ratio 10.98
Current Ratio 11.01

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

NEUP
ROA (LTM) 0.00%
ROE (LTM) 0.00%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

NEUP
Debt Ratio Lower is generally better. Negative is bad. 0.15
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.85

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

NEUP
Trailing PE 0.45
Forward PE NM
P/S (TTM) 145.56
P/B 1263.00
EV/R 26194.63
EV/Ebitda NM

FAQs

What is Neuphoria Therapeutics Inc share price today?

Neuphoria Therapeutics Inc (NEUP) share price today is $6.48

Can Indians buy Neuphoria Therapeutics Inc shares?

Yes, Indians can buy shares of Neuphoria Therapeutics Inc (NEUP) on Vested. To buy Neuphoria Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in NEUP stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Neuphoria Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Neuphoria Therapeutics Inc (NEUP) via the Vested app. You can start investing in Neuphoria Therapeutics Inc (NEUP) with a minimum investment of $1.

How to invest in Neuphoria Therapeutics Inc shares from India?

You can invest in shares of Neuphoria Therapeutics Inc (NEUP) via Vested in three simple steps:

  • Click on Sign Up or Invest in NEUP stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Neuphoria Therapeutics Inc shares
What is Neuphoria Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Neuphoria Therapeutics Inc (NEUP) is $12.72. The 52-week low price of Neuphoria Therapeutics Inc (NEUP) is $2.12.

What is Neuphoria Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Neuphoria Therapeutics Inc (NEUP) is 0.452

What is Neuphoria Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Neuphoria Therapeutics Inc (NEUP) is 1263.00

What is the Market Cap of Neuphoria Therapeutics Inc?

The market capitalization of Neuphoria Therapeutics Inc (NEUP) is $11.71M

What is Neuphoria Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Neuphoria Therapeutics Inc is NEUP

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top